Gantenerumab
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Gantenerumab</th>
</tr>
<tr>
<td class="label">Measure</td>
<td>GRADUATE I</td>
</tr>
<tr>
<td class="label">CDR-SB difference vs placebo</td>
<td>-0.31 points</td>
</tr>
<tr>
<td class="label">Relative reduction in decline</td>
<td>8%</td>
</tr>
<tr>
<td class="label">Statistical significance</td>
<td>Not significant</td>
</tr>
<tr>
<td class="label">Adverse Event</td>
<td>Gantenerumab</td>
</tr>
<tr>
<td class="label">ARIA-E (edema)</td>
<td>24.9%</td>
</tr>
<tr>
<td class="label">Symptomatic ARIA-E</td>
<td>5.0%</td>
</tr>
<tr>
<td class="label">ARIA-H (microhemorrhages)</td>
<td>Associated with ARIA-E</td>
</tr>
<tr>
<td class="label">Injection site reactions</td>
<td>24.4%</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Gantenerumab</td>
</tr>
<tr>
<td class="label">Developer</td>
<td>Roche</td>
</tr>
<tr>
<td class="label">Administration</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>510 mg q2w</td>
</tr>
<tr>
<td class="label">Amyloid reduction</td>
<td>~50%</td>
</tr>
<tr>
<td class="label">Amyloid-negative rate</td>
<td>28%</td>
</tr>
<tr>
<td class="label">CDR-SB benefit</td>
<td>Not significant</td>
</tr>
<tr>
<td class="label">ARIA-E rate</td>
<td>24.9%</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Discontinued</td
...Gantenerumab
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Gantenerumab</th>
</tr>
<tr>
<td class="label">Measure</td>
<td>GRADUATE I</td>
</tr>
<tr>
<td class="label">CDR-SB difference vs placebo</td>
<td>-0.31 points</td>
</tr>
<tr>
<td class="label">Relative reduction in decline</td>
<td>8%</td>
</tr>
<tr>
<td class="label">Statistical significance</td>
<td>Not significant</td>
</tr>
<tr>
<td class="label">Adverse Event</td>
<td>Gantenerumab</td>
</tr>
<tr>
<td class="label">ARIA-E (edema)</td>
<td>24.9%</td>
</tr>
<tr>
<td class="label">Symptomatic ARIA-E</td>
<td>5.0%</td>
</tr>
<tr>
<td class="label">ARIA-H (microhemorrhages)</td>
<td>Associated with ARIA-E</td>
</tr>
<tr>
<td class="label">Injection site reactions</td>
<td>24.4%</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Gantenerumab</td>
</tr>
<tr>
<td class="label">Developer</td>
<td>Roche</td>
</tr>
<tr>
<td class="label">Administration</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>510 mg q2w</td>
</tr>
<tr>
<td class="label">Amyloid reduction</td>
<td>~50%</td>
</tr>
<tr>
<td class="label">Amyloid-negative rate</td>
<td>28%</td>
</tr>
<tr>
<td class="label">CDR-SB benefit</td>
<td>Not significant</td>
</tr>
<tr>
<td class="label">ARIA-E rate</td>
<td>24.9%</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Discontinued</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">SCarlet RoAD (2014)</td>
<td>225 mg</td>
</tr>
<tr>
<td class="label">SCarlet RoAD OLE</td>
<td>1200 mg</td>
</tr>
<tr>
<td class="label">GRADUATE I</td>
<td>1020 mg</td>
</tr>
<tr>
<td class="label">GRADUATE II</td>
<td>1020 mg</td>
</tr>
</table>
Introduction
Add Open Questions Section Addressing Comparative Evidence is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Gantenerumab (RO4909832, RG7412) is a fully human anti-[amyloid-beta](/proteins/amyloid-beta) (Aβ) immunoglobulin G1 (IgG1) monoclonal antibody developed by Roche/Genentech/MorphoSys for the treatment of [Alzheimer's disease](/diseases/alzheimers-disease). Designed to bind with high affinity to aggregated forms of Aβ — including oligomers, fibrils, and plaques — gantenerumab was one of the most extensively studied anti-amyloid therapeutics in clinical development[@bohrmann2012].
Despite strong preclinical rationale and partial amyloid reduction in clinical trials, gantenerumab failed to meet its primary clinical endpoints in the Phase 3 GRADUATE I and GRADUATE II trials, and Roche discontinued development in January 2023[@roche2023]. The gantenerumab program provides critical lessons about dose optimization, amyloid clearance thresholds, and the relationship between biomarker changes and clinical benefit.
Mechanism of Action
Gantenerumab operates through three complementary mechanisms to clear [amyloid-beta](/proteins/amyloid-beta) from the brain[@bohrmann2012][@abbright2019]:
The primary clearance mechanism involves Fc gamma receptor-mediated phagocytosis. After gantenerumab binds to aggregated Aβ on plaque surfaces, the IgG1 Fc domain engages Fc gamma receptors on [microglia](/cell-types/microglia), triggering engulfment and degradation of the antibody-Aβ complexes.
Direct Plaque Disruption
Gantenerumab can bind to multiple Aβ species on plaque surfaces, potentially destabilizing the aggregated structure and facilitating disaggregation.
Peripheral Sink Effect
Like other anti-amyloid antibodies, gantenerumab may create a peripheral sink by binding plasma Aβ, promoting efflux from the brain.
Epitope Specificity
Gantenerumab binds to a conformational epitope present on Aβ aggregates, with preference for N-terminal regions of fibrillar Aβ.
Clinical Development
Early Phase Studies
Gantenerumab underwent extensive Phase 1 and Phase 2 testing:
- First-in-human studies established safety and tolerability
- Phase 1b showed dose-dependent amyloid reduction
- Phase 2scarlet AD showed promising biomarker effects
Phase 3: GRADUATE I and II
The GRADUATE I (NCT03444870) and GRADUATE II (NCT03443973) trials were identical, randomized, double-blind, placebo-controlled Phase 3 studies[@roche2023]:
- Population: Ages 50-90 with mild cognitive impairment or mild dementia due to AD
- Amyloid confirmation: Positive amyloid PET or CSF Aβ42/40 ratio
- Dosing: Subcutaneous gantenerumab titrated to 510 mg every 2 weeks
- Primary endpoint: Change from baseline in CDR-SB at week 116
- Duration: 116 weeks (approximately 2.2 years)
Primary Results
Both GRADUATE trials failed to meet their primary endpoint[@roche2023]:
For comparison, [lecanemab](/therapeutics/lecanemab) achieved a 27% reduction (p<0.001) in the CLARITY AD trial, and [donanemab](/therapeutics/donanemab) achieved a 35% reduction (p<0.001) in TRAILBLAZER-ALZ 2.
Biomarker Results
Despite clinical failure, gantenerumab produced meaningful biomarker changes[@salloway2022]:
- [Amyloid PET](/entities/amyloid-pet) reduction: -66.44 centiloids (GRADUATE I) and -56.46 centiloids (GRADUATE II) difference from placebo at week 116
- Amyloid clearance to negative: Only 28% of gantenerumab-treated participants reached amyloid-negative PET status, compared to approximately 68% for [lecanemab](/entities/lecanemab) and approximately 80% for donanemab
- CSF biomarkers: Reduction in CSF p-[tau](/proteins/tau), total [tau](/proteins/tau), and neurogranin, indicating downstream effects on tau pathology and synaptic dysfunction
Safety Profile
The safety profile was generally consistent with other anti-amyloid antibodies[@roche2023]:
Most ARIA events were mild to moderate and resolved without sequelae.
Lessons Learned
The gantenerumab program provides several important lessons:
Dose and Titration
- Subcutaneous administration allowed higher doses but may have limited brain penetration
- The 510 mg biweekly dose may have been suboptimal for achieving complete amyloid clearance
- Earlier, more aggressive dosing might have produced different results
Amyloid Clearance Threshold
- Only 28% of participants achieved amyloid negativity vs. 68-80% for newer antibodies
- This suggests incomplete target engagement may have limited efficacy
- The relationship between amyloid reduction and clinical benefit may require near-complete clearance
Trial Design
- Longer trial duration (116 weeks) may not have compensated for insufficient amyloid clearance
- Baseline amyloid burden may have been higher than in successful trials
Comparison with Other Anti-Amyloid Therapies
Current Status
Roche discontinued gantenerumab development in January 2023 following the GRADUATE trial results. However, the learnings from this program have informed the development of next-generation anti-amyloid therapies.
Background
The study of Add Open Questions Section Addressing Comparative Evidence has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Allen Brain Atlas Resources
- [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
- [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
- [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Amyloid-Beta](/proteins/amyloid-beta)
- [Lecanemab](/entities/lecanemab)
- [Donanemab](/entities/donanemab)
- Anti-Amyloid Immunotherapy
External Links
- [ClinicalTrials.gov: GRADUATE I](https://clinicaltrials.gov/study/NCT03444870)
- [ClinicalTrials.gov: GRADUATE II](https://clinicaltrials.gov/study/NCT03444816)
- [Roche Clinical Trials](https://forpatients.roche.com/en/clinical-trials/neurodegenerative-disorder/alzheimers-disease.html)
Mechanism of Action
Mermaid diagram (expand to render)
Clinical Trial Results
Administration
- Route: Subcutaneous injection
- Frequency: Every 2 weeks
- Titration: Monthly to target dose
References
[Bohrmann, B., et al. (2012). Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-beta binding and elicits immune-mediated clearance. Journal of Alzheimer's Disease, https://doi.org/10.3233/JAD-2012-120943 (2012)](https://doi.org/10.3233/JAD-2012-120943](https://doi.org/10.3233/JAD-2012-120943](https://doi.org/10.3233/JAD-2012-120943)
Unknown, Roche. (2023). Roche to discontinue gantenerumab Phase III program in Alzheimer's disease. Press Release (2023)
[Abbright, C., et al. (2019). Gantenerumab reduces amyloid-β plaques in patients with Alzheimer's disease. Alzheimer's & Dementia, https://doi.org/10.1016/j.jalz.2019.06.4959 (2019)](https://doi.org/10.1016/j.jalz.2019.06.4959](https://doi.org/10.1016/j.jalz.2019.06.4959](https://doi.org/10.1016/j.jalz.2019.06.4959)
[Klein, G., et al. (2019). Gantenerumab reduces CSF p-tau in patients with early Alzheimer's disease. Alzheimer's & Dementia, https://doi.org/10.1016/j.jalz.2019.06.4960 (2019)](https://doi.org/10.1016/j.jalz.2019.06.4960](https://doi.org/10.1016/j.jalz.2019.06.4960](https://doi.org/10.1016/j.jalz.2019.06.4960)
[Salloway, S., et al. (2022). Amyloid-related imaging abnormalities in the GRADUATE trials. Alzheimer's & Dementia, https://doi.org/10.1002/alz.12788 (2022)](https://doi.org/10.1002/alz.12788](https://doi.org/10.1002/alz.12788](https://doi.org/10.1002/alz.12788)